X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.
Lead Product(s): Lunresertib,Camonsertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Repare Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 12, 2024
Details:
RP-3500 (camonsertib), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase). It is evaluated for non-small cell lung cancer.
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2024
Details:
FDA granted Fast Track designation to RP-6306 (lunresertib) in combination with RP-3500 (camonsertib) for CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.
Lead Product(s): Lunresertib,Camonsertib
Therapeutic Area: Oncology Product Name: RP-6306
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Details:
Under the termination, Repare will regain global development and commercialization rights to RP-3500 (camonsertib), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase).
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,325.0 million Upfront Cash: $125.0 million
Deal Type: Termination February 12, 2024
Details:
Roche is responsible for the development and commercialization of RP-3500/RG6526 (camonsertib), a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene.
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: RG6526
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,338.6 million Upfront Cash: $125.0 million
Deal Type: Licensing Agreement January 25, 2024
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for treatment of solid tumors with specific genome instability related genomic alterations including those in the ATM (ataxia-telangiectasia mutated) gene.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
RP-3500, orally-administered ataxia telangiectasia and Rad3-related inhibitor currently in Phase 1/2 TRESR trial clinical development in patients with DNA damage repair, loss-of-function and mutant tumors.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Dose optimization provides robust evidence to advance RP-3500, a potent and selective oral small molecule inhibitor of ATR into Phase 2 studies with a recommended dose and schedule, for the treatment of solid tumors.
Lead Product(s): Camonsertib,Talazoparib,Gemcitabine
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations.
Lead Product(s): Camonsertib,Talazoparib
Therapeutic Area: Oncology Product Name: RP-3500
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Repare intends to file an IND application in the 2Q20 for lead candidate,RP-3500, an oral small molecule inhibitor for the treatment of solid tumors.
Lead Product(s): Camonsertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
